Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Tepotinib Hydrochloride Hydrate: brief review of its R&D progress and the clinical result in 2023 ESMO
ESMO 2023
4 min read
Tepotinib Hydrochloride Hydrate: brief review of its R&D progress and the clinical result in 2023 ESMO
17 November 2023
On 23 Oct 2023, liquid biopsies (LBx) and tissue biopsies (TBx) for identifying MET exon 14 (METex14) skipping in advanced NSCLC: Analyses from the phase II VISION study of tepotinib was reported at the ESMO Congress.
Read →
An In-depth Analysis of Tolcapone's R&D Progress and Mechanism of Action on Drug Target
Drug Insights
4 min read
An In-depth Analysis of Tolcapone's R&D Progress and Mechanism of Action on Drug Target
17 November 2023
This article summarized the latest R&D progress of Tolcapone, the Mechanism of Action for Tolcapone, and the drug target R&D trends for Tolcapone.
Read →
Biological Glossary | What is Neoantigen?
Bio Sequence
2 min read
Biological Glossary | What is Neoantigen?
17 November 2023
In biology, a neoantigen refers to a novel antigen that arises from a mutation in the DNA of a normal cell.
Read →
BioRay begins Phase I trial for BRY812, a novel LIV-1 antibody drug conjugate, with its first patient
Latest Hotspot
3 min read
BioRay begins Phase I trial for BRY812, a novel LIV-1 antibody drug conjugate, with its first patient
17 November 2023
BioRay introduces the initiation of its Phase I clinical trial with the first patient for BRY812, a new LIV-1 focused antibody drug conjugate.
Read →
What are CDK4 inhibitors and how do you quickly get the latest development progress?
What are CDK4 inhibitors and how do you quickly get the latest development progress?
17 November 2023
CDK4 inhibitors can inhibit the formation of complexes between CDK4 and cyclin D, block ATP binding, thereby severing upstream growth signals, and prevent the transition from G1 to S phase.
Read →
Triclabendazole: Detailed Review of its Transformative R&D Success
Drug Insights
4 min read
Triclabendazole: Detailed Review of its Transformative R&D Success
17 November 2023
This article summarized the latest R&D progress of Triclabendazole, the Mechanism of Action for Triclabendazole, and the drug target R&D trends for Triclabendazole.
Read →
Biological Glossary | What is Mutation?
Bio Sequence
2 min read
Biological Glossary | What is Mutation?
17 November 2023
In biology, a mutation is a permanent alteration to the nucleotide sequence of the genome of an organism, virus, or extrachromosomal DNA.
Read →
Ventyx Biosciences announces Phase 2 results for VTX958 in psoriasis and provides a company update
Latest Hotspot
3 min read
Ventyx Biosciences announces Phase 2 results for VTX958 in psoriasis and provides a company update
17 November 2023
Ventyx Biosciences reports outcomes of the second phase study of VTX958 in moderate-to-severe plaque psoriasis patients and delivers a company update.
Read →
Prazepam Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
Drug Insights
4 min read
Prazepam Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
17 November 2023
This article summarized the latest R&D progress of Prazepam, the Mechanism of Action for Prazepam, and the drug target R&D trends for Prazepam.
Read →
Osimertinib mesylate: brief review of its R&D progress and the clinical result in 2023 ESMO
ESMO 2023
4 min read
Osimertinib mesylate: brief review of its R&D progress and the clinical result in 2023 ESMO
16 November 2023
The 2023 ESMO Congress marked a pivotal moment with the disclosure of a clinical trial for Osimertinib mesylate in EGFR-mutated NSCLC patients, opening avenues for further increases in its clinical efficacy.
Read →
Sale of GLP-1 Small Molecule to Eli Lilly, Chugai Pharmaceutical Discloses Latest KRAS Macrocyclic Patent
Hot Spotlight
7 min read
Sale of GLP-1 Small Molecule to Eli Lilly, Chugai Pharmaceutical Discloses Latest KRAS Macrocyclic Patent
16 November 2023
Last year belonged to the realm of Pfizer's COVID-19 small molecule treatments, while this year is dominated by GLP-1 injectable and oral therapies.
Read →
What are CDK9 inhibitors and how do you quickly get the latest development progress?
What are CDK9 inhibitors and how do you quickly get the latest development progress?
16 November 2023
The overexpression of the anti-apoptotic factor Myeloid Cell Leukemia 1 (MCL-1), caused by the activation of CDK9, will lead to the transformation of malignant tumor cells. Therefore, inhibiting CDK9 will downregulate MCL-1, thereby suppressing tumor growth.
Read →